Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Melanoma × Propranolol × Clear all

Phase

Status

Unknown 1 Terminated 1 Suspended 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hemangioma 3 Prostatic Neoplasms 2 Uterine Cervical Neoplasms 1 Melanoma 1 Hemangioma, Cavernous, Central Nervous System 1 Breast Neoplasms 1 Anxiety Disorders 1

Interventions

pembrolizumab 41 Ipilimumab 37 Cyclophosphamide 36 Nivolumab 33 aldesleukin 25 Interleukin-2 19 fludarabine 18 Vemurafenib 18 dabrafenib 14 fludarabine phosphate 13 trametinib 12 Temozolomide 12 Radiosurgery 9 spartalizumab 8 cobimetinib 8 Dacarbazine 8 binimetinib 7 poly ICLC 6 encorafenib 6 Radiotherapy 6 Introns 6 CTLA-4 Antigen 6 Biopsy 6 montanide ISA 51 5 Interferon alpha-2 4 Immunohistochemistry 4 Celecoxib 4 Bevacizumab 4 tovorafenib 3 sotigalimab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01705392 2017-02-24

Bevacizumab vs Dacarbazine in Metastatic Melanoma

Haukeland University Hospital

Phase 2 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡